Ro vs. Hims & Hers: What the Compounding Crackdown Actually Did

By / September 30, 2026
Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/

On February 7, 2026, Hims & Hers pulled a $49 compounded copy of Novo Nordisk’s Wegovy pill off the market three days after launching it. In the 48 hours before that reversal, the FDA had publicly called out the company, Novo Nordisk had announced plans to sue, and the general counsel of the U.S. Department of Health and Human Services had referred Hims & Hers to the Department of Justice for potential Food, Drug, and Cosmetic Act violations.1 That sequence is the clearest data point available on how fast the telehealth “compounding loophole” can close once a federal agency decides to use it.

The broader story is that the compounding era that built Hims & Hers into a weight-loss powerhouse is over, and both companies have already moved on to what comes next: branded-drug distribution deals, international acquisitions, and a 2026 patent cliff that hands cash-pay platforms a new category of drugs to sell the moment they go generic. This analysis updates the public record on the Ro–Hims & Hers rivalry with the regulatory actions, financial results, and acquisitions that have occurred since, and corrects several patent-timeline assumptions that are easy to get wrong.

MetricHims & Hers (NYSE: HIMS)Ro (private)
Latest reported quarterly revenue$753.2 million, Q2 2026, up 38% YoY2Not publicly disclosed since 2024 estimate of ~$598M annualized3
Subscribers / customers2.891 million, up 19% YoY2Not disclosed
Full-year 2026 revenue guidance$3.1–$3.3 billion4N/A
Q2 2026 gross margin64%, down from 76% in Q2 20252N/A
Q2 2026 net resultNet loss of $86.3 million2N/A
2025 full-year resultRevenue $2.35B (+59% YoY); net income $128M5N/A
Total funding raisedPublic company (NYSE: HIMS)$1.03 billion across 8 rounds; last disclosed round Feb 2022 at $150M6

The Compounding Era Is Over. Here Is the Exact Timeline.

The source of Hims & Hers’ 2024 growth acceleration and the source of its 2025–2026 regulatory exposure are the same thing: compounded semaglutide and tirzepatide sold under the FDA’s drug-shortage exemptions. That exemption no longer exists in the form it did in 2024, and the shutdown happened in discrete, dated steps rather than a single ruling.

Why the Shortage Exemption Existed

Under the Federal Food, Drug, and Cosmetic Act, a drug that appears on the FDA’s official shortage list can be compounded by state-licensed 503A pharmacies and federally regulated 503B outsourcing facilities even though a patient-specific prescription and individualized formulation would normally be required. Tirzepatide (Zepbound, Mounjaro) and semaglutide (Ozempic, Wegovy) both spent 2022–2024 on that list, which is what let Hims & Hers, Ro, and dozens of smaller telehealth platforms sell mass-produced “copies” at a fraction of the branded price.

The Shutdown, Month by Month

DateEventSource
October 2024FDA declares the tirzepatide shortage resolvedFDA Drug Shortages Database; Federal Register docket 2026-085527
February 2025FDA declares the semaglutide shortage resolved
February 18, 2025Enforcement discretion ends for tirzepatide at 503A pharmacies
March 19, 2025Enforcement discretion ends for tirzepatide at 503B outsourcing facilities; mass compounding effectively stops
April 22, 2025Enforcement discretion ends for semaglutide at 503A pharmacies
May 22, 2025Enforcement discretion ends for semaglutide at 503B outsourcing facilities
September 9, 2025FDA sends warning letters to roughly 100 companies over deceptive GLP-1 marketing; Hims & Hers receives two, for its Hims and Hers brandsFDA MARCS-CMS 716567 and 7168258,9
February 3–4, 2026Hims & Hers launches a $49/month compounded Wegovy-pill copy; Novo Nordisk says it will sueForbes10
February 6, 2026HHS General Counsel Mike Stuart refers Hims & Hers to the DOJ for potential FDCA and Title 18 violationsHHS General Counsel statement11
February 7, 2026Hims & Hers withdraws the compounded pill after “constructive conversations with stakeholders”Frierlevitt legal analysis12
April–May 2026FDA proposes permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list, closing the shortage-based pathway even if a future shortage recursFederal Register docket 2026-08552, 91 FR 234317

What This Means for Both Companies Today

Compounded semaglutide and tirzepatide are not banned outright. Narrow, genuinely patient-specific 503A compounding — for a documented allergy to an inactive ingredient, for example — remains legal.13 What ended is the mass-market model: bulk-produced, standard-dose “copies” marketed as interchangeable with Wegovy or Zepbound at a lower price. That is precisely the model Hims & Hers built its 2024 growth around, and precisely what the FDA’s September 2025 warning letters targeted.

Two Different Fallout Patterns

Ro was not named in the FDA’s September 2025 warning-letter batch and had no compounding partnership with Novo Nordisk to lose; Novo’s June 2025 termination applied specifically to Hims & Hers, and Novo continued working with Ro and LifeMD on branded-drug access.14 Ro’s collaborative posture — distributing FDA-approved drugs through manufacturer partnerships rather than compounding copies — meant the 2025–2026 enforcement wave landed almost entirely on Hims & Hers and on smaller, less differentiated telehealth compounders.

Financial Reality Check: The Mix Shift Is Already in the Numbers

The original telehealth-duopoly narrative described a company converting compounding profits into EBITDA expansion. The Q2 2026 results show the opposite pressure: revenue is still growing fast, but the mix shift away from high-margin compounded drugs toward lower-margin branded products and lower-margin international revenue has compressed gross margin by 12 points year over year.

Hims & Hers metricQ2 2025Q2 2026Change
Total revenue$544.8M$753.2M+38%2
U.S. revenue$537.3M$621.8M+16%2
International revenue~$7.5M$131.4M+17x, driven by the June 2026 Eucalyptus acquisition2,15
Gross margin76%64%-12 points2
Net income / (loss)$42.5M income($86.3M) lossSwing to loss2
Adjusted EBITDA$82.2M$60.3M-27%2
Subscribers2.43M2.891M+19%2
Monthly revenue per average subscriber$76$92+21%2

“We’re rebuilding the consumer health experience from the ground up with a doctor-led AI clinical engine, and the depth and breadth of our relationships with customers worldwide has never been greater.” — Andrew Dudum, co-founder and CEO, Hims & Hers, Q2 2026 shareholder letter4

Why Margin Compressed at the Same Time Revenue Accelerated

Three forces hit gross margin simultaneously in 2026: the shift from self-manufactured compounded drugs (near-100% gross margin on the drug itself) to distributed branded product, where Hims & Hers pays wholesale or partner pricing; the closing of the Eucalyptus acquisition, whose lower-margin international revenue is now consolidated; and a $28.5 million restructuring charge booked within cost of revenue in the first half of 2026.16 Free cash flow was negative $68 million in Q2 2026, which management attributed to working-capital demands of scaling branded weight-loss inventory rather than to the compounding pullback itself.17

Free Cash Flow Is the Metric to Watch, Not Revenue Growth

Revenue growth of 38% headline year-over-year looks strong, but it is now driven substantially by acquired international revenue (Eucalyptus contributed roughly $40 million of the $753.2 million in Q2 2026) rather than organic domestic subscriber growth, which decelerated to 16% domestically.17 Management has guided to positive free cash flow in the second half of 2026 and reiterated a 2030 target of $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA.2,4

Hims & Hers Went Global While the U.S. Compounding Story Was Collapsing

This is the single largest development the original telehealth-duopoly narrative missed entirely: while U.S. regulators were closing the compounding pathway, Hims & Hers spent 2025–2026 building an international arm through acquisition, not organic expansion.

AcquisitionMarket(s)Deal termsStatus
ZAVAUnited Kingdom, Germany, France, IrelandNot fully disclosedClosed, referenced in FY2025 shareholder letter18
LivewellCanadaNot fully disclosedClosed18
Eucalyptus (parent of Juniper, Pilot, Compound)Australia, UK, Germany, Ireland, Canada, JapanUp to $1.15 billion total; ~$240 million cash at closing, remainder in guaranteed and earnout payments through early 2029Announced Feb 19, 2026; closed June 2, 202615,19,20

Eucalyptus brought roughly 775,000 customers and an annualized revenue run rate north of $450 million, with triple-digit year-over-year growth in every quarter of 2025.21 Its former CEO, Tim Doyle, became Hims & Hers’ SVP of International.19 The company frames the deal, and its broader international push, as diversification beyond U.S. GLP-1 exposure at exactly the moment domestic regulatory risk peaked — the Eucalyptus deal was announced two weeks after the DOJ referral and the withdrawn $49 pill.21

Why the Timing Is Not a Coincidence

Analysts covering the Eucalyptus deal noted explicitly that it followed “mounting regulatory and legal scrutiny in the United States” and represented “a deliberate pivot toward global expansion.”21 International revenue carries none of the FDCA misbranding exposure that domestic compounded-drug marketing does, and none of the direct competitive collision with Novo Nordisk and Eli Lilly’s U.S. self-pay channels.

Ro’s Model: Branded-Drug Distribution, Not Compounding

Ro’s core strategic bet — integrate with manufacturers rather than compound around them — has held up through the 2025–2026 enforcement wave better than Hims & Hers’ vertical-manufacturing bet, largely because Ro was not the entity being sued or referred to the DOJ.

The LillyDirect Integration, With Real Prices

Ro connected to Eli Lilly’s LillyDirect self-pay channel in December 2024, offering Zepbound single-dose vials at $399/month (2.5 mg) and $549/month (5 mg) — list prices set by Lilly, not negotiated by Ro.22 In April 2026, Ro added the FDA-approved Zepbound KwikPen, a prefilled multi-dose pen, to the same integration.23

Ro Also Works With Novo Nordisk — On Novo’s Terms

In January 2026, Novo Nordisk partnered with Ro (among other telehealth platforms) to distribute the newly FDA-approved oral Wegovy pill — the same drug category Hims & Hers’ compounded copy was undercutting on price a few weeks later.24 This is a meaningful nuance: Ro is not “the anti-Hims” in some absolute sense; it works with both major GLP-1 manufacturers, on branded, on-label terms, which is precisely the arrangement that kept it out of the FDA’s and DOJ’s crosshairs.

Ro’s Diagnostics Acquisitions Are Older Than They Look

Ro’s Modern Fertility ($225 million) and Kit acquisitions, often described as recent strategic moves, both closed in 2021 — Modern Fertility in May and Kit in June.25,26 Ro added a third fertility acquisition, Dadi (sperm testing and storage, reported at roughly $100 million), in March 2022, rebranding it as the Ro Sperm Kit.27 These are now mature, integrated parts of Ro’s platform rather than new moves — a distinction that matters for anyone modeling M&A cadence or valuing the “diagnostics pivot” as a 2025–2026 story specific to either company.

The YourBio Acquisition, With the Actual Purchase Price

Hims & Hers announced its agreement to acquire YourBio Health on December 3, 2025, with the deal closing January 30, 2026.28,29 Public filings put the total transaction value at $153.0 million — $142.4 million in cash plus $10.6 million in contingent consideration — a figure the original announcement did not disclose.29 YourBio’s TAP device uses bladeless microneedles “thinner than an eyelash” to collect capillary blood samples, and CEO Andrew Dudum has told the Wall Street Journal he expects the resulting diagnostics offering to become a $1 billion business over time.30

What the Patents Actually Cover

YourBio’s IP portfolio covers three distinct technical areas: microneedle array design and manufacturing, capillary sample-handling mechanisms, and device-integration methods that connect the collection hardware to lab-processing workflows.31 This is a materially broader patent estate than a single “painless needle” patent — it is what allows Hims & Hers to potentially license or extend the underlying HALO platform into future diagnostic products rather than a single blood-draw SKU.

The 2026 Patent Cliff: Correcting the Dates

Both companies’ pharmaceutical strategies increasingly depend on timing generic entry accurately. Several widely cited patent-expiration dates for the two drugs most relevant to this sector — Eliquis and Januvia — are technically correct but operationally misleading, because a composition-of-matter patent’s expiration date is not the same as the date generics can actually launch.

Eliquis (Apixaban): Three Different Dates, Only One Matters for 2026

Bristol Myers Squibb and Pfizer’s original apixaban compound patent (U.S. 6,967,208), filed in 2002, was extended by patent term extension to November 21, 2026.32 Pediatric exclusivity pushes the operative composition-patent date to May 2027. But neither date controls actual generic entry for most filers: under settlement agreements BMS and Pfizer reached with the ANDA filers that originally challenged the patent, licensed generic entry is set for April 1, 2028 — a negotiated date that falls between the composition patent’s exclusivity end and a separate formulation patent’s 2031 expiration.33 A smaller set of later filers, including Azurity Pharmaceuticals (which filed a Paragraph IV challenge in November 2025 against a formulation patent, not the composition patent) and Aurobindo Pharma (notice letters in May and June 2026), remain in active litigation rather than settlement, which could open a narrower window before 2028 if BMS and Pfizer lose.34,35

Methodology Note on the Eliquis Timeline

This distinction — settlement date versus patent-expiration date — is not a minor technicality for a telehealth platform planning to sell generic apixaban. A platform that builds a launch plan around the November 2026 headline date rather than the April 2028 settlement date will miscalculate its addressable-market timing by roughly seventeen months for the majority of the market, even though the November 2026 date is factually accurate as a patent-expiration date.33

Januvia (Sitagliptin): The Settlement Predates the Patent Expiration

Merck’s core sitagliptin compound patent expired in 2023. A separate patent covering the dihydrogen phosphate salt and polymorphic forms of sitagliptin — the actual form used in Januvia — expires November 24, 2026, with pediatric exclusivity extending it to May 2027.36 However, Merck settled with more than two dozen generic manufacturers years ago, and those settlements license generic Januvia and Janumet entry in the U.S. starting in May 2026 — six months before the underlying salt patent’s own listed expiration date — with Janumet XR following in July 2026.37,38 A separate co-formulation patent covering Janumet specifically runs to January 21, 2029.39 Merck has continued to litigate against filers proposing non-settled generic forms; a federal court in West Virginia ruled in Merck’s favor against Viatris in 2026, finding both asserted patents valid and infringed.38

DrugActive ingredientCompanyListed patent expirationActual first licensed generic entrySource
EliquisApixabanBMS / PfizerNov 21, 2026 (composition patent, post-PTE); May 2027 with pediatric exclusivity; 2031 for a separate formulation patentApril 1, 2028 for settled filers; earlier only if active litigants (Azurity, Aurobindo) prevail33, 34
Januvia / JanumetSitagliptinMerckNov 24, 2026 (salt/polymorph patent); May 2027 with pediatric exclusivityMay 2026 (Januvia/Janumet) and July 2026 (Janumet XR) under settlement — before the listed patent date36, 37, 39

Why This Matters More for Telehealth Platforms Than for Traditional Pharmacies

A cash-pay telehealth platform’s entire margin advantage depends on being the first channel to offer a low-cost generic once it is legally available. Getting the settlement date wrong by even a quarter, in either direction, either forfeits early-mover margin or creates legal exposure from launching before authorization. This is the exact function DrugPatentWatch’s Orange Book and litigation-tracking data serves for platforms modeling entry into cardiovascular (Eliquis) and metabolic (Januvia) categories as their next post-GLP-1 growth vertical.

Corporate Practice of Medicine: The Legal Structure Underneath Both Platforms

Ro and Hims & Hers both operate in states with Corporate Practice of Medicine (CPOM) laws, which generally bar non-physician-owned entities from employing physicians to deliver care. Both companies use a “friendly PC” structure: a physician-owned professional corporation holds the actual medical practice and provider relationships, while the telehealth company provides administrative, technology, and “management services” under a separate services agreement. This structure is long-standing in U.S. telehealth and is not new to either company, but it remains the underlying legal architecture regulators and plaintiffs’ attorneys scrutinize when they allege that a platform is exerting undue clinical influence — for example, by steering patients toward a specific formulation or manufacturer based on margin rather than clinical fit, which was Hims & Hers’ own public rebuttal to Novo Nordisk’s June 2025 termination.40

The PBM Counter-Pressure Is Real, but It Stabilized in 2026

Pharmacy Benefit Manager customer satisfaction, tracked annually by Pharmaceutical Strategies Group (PSG), fell from 7.6 to 7.1 (on a 10-point scale) between 2024 and 2025 — described by PSG’s president as “a tipping point.”41 The 2026 report shows that decline stabilizing rather than continuing: overall satisfaction held at 7.2, nearly flat versus 2025, though satisfaction with the three largest PBMs (CVS Caremark, Express Scripts, OptumRx) edged up while non-Big-3 PBM satisfaction fell from 7.9 to 7.3.42 Roughly two-thirds of plan sponsors rate their desire for industry change at 7 or higher out of 10, and only 55% report satisfaction with PBM net pricing on specialty medications.42 This is the structural opening that cash-pay telehealth platforms are selling against, but the data does not show an accelerating PBM collapse in 2026 — it shows a market that cratered in 2024–2025 and then plateaued at a historically low but stable level.

Definitions

503A vs. 503B Compounding

Section 503A of the FDCA covers traditional compounding pharmacies that prepare drugs for an individual, identified patient based on a specific prescription and are primarily overseen by state boards of pharmacy. Section 503B covers “outsourcing facilities” that may compound in bulk without patient-specific prescriptions, subject to federal cGMP manufacturing standards and FDA oversight. Both pathways permit compounding a copy of a commercially available drug only while that drug appears on the FDA’s official shortage list; once a shortage is declared resolved, both pathways lose that legal basis, though 503A retains a separate, narrower exemption for genuine patient-specific clinical need unrelated to shortage status.7,13

Paragraph IV Certification

A certification filed by a generic or 505(b)(2) applicant asserting that a patent listed in the FDA’s Orange Book for the reference drug is invalid, unenforceable, or will not be infringed by the proposed generic. A successful first-to-file Paragraph IV challenger can be awarded 180 days of generic marketing exclusivity before other generics may enter.

Corporate Practice of Medicine (CPOM)

State-law doctrine, present in a majority of U.S. states in varying strength, prohibiting business corporations from employing physicians to practice medicine or from exercising control over physicians’ clinical judgment. Telehealth platforms structure around CPOM using physician-owned professional corporations paired with management-services agreements.

Methodology

Financial figures for Hims & Hers are drawn directly from the company’s SEC filings (Forms 8-K, 10-Q, and 10-K) for the periods stated; Ro, as a private company, discloses far less, and figures attributed to Ro are third-party estimates clearly marked as such. Patent-expiration and generic-entry dates are drawn from the companies’ own SEC risk-factor and legal-proceedings disclosures (Merck, BMS, and Pfizer 10-Q/10-K filings) rather than secondary compilations, except where noted. Where a settlement date differs from a patent’s listed expiration date, both are reported, since relying on either figure alone materially misstates the operative generic-entry date. Regulatory timeline dates (FDA shortage resolutions, enforcement-discretion deadlines, warning-letter dates) are drawn from FDA.gov, the Federal Register, and direct quotations from the HHS General Counsel’s public statement. This analysis does not independently verify litigation outcomes beyond what is stated in the cited public filings and does not offer legal advice on any pending matter.

Key Takeaways

  • The mass-compounding model that built Hims & Hers’ 2024 growth ended in stages between October 2024 and May 2025, and a February 2026 attempt to relaunch a compounded Wegovy-pill copy was withdrawn within three days of an HHS referral to the DOJ.
  • Ro was not named in the FDA’s September 2025 warning-letter wave and continued branded-drug distribution partnerships with both Eli Lilly and, as of January 2026, Novo Nordisk — the manufacturer that had already cut off Hims & Hers.
  • Hims & Hers’ Q2 2026 results show 38% revenue growth alongside a 12-point gross-margin decline and a swing to a net loss, driven by the shift from compounded to branded and international revenue.
  • Hims & Hers’ international expansion — ZAVA, Livewell, and the up-to-$1.15-billion Eucalyptus acquisition — is the largest strategic development the original telehealth-duopoly narrative omitted, and its timing tracks closely with the peak of U.S. regulatory pressure.
  • Eliquis and Januvia generic-entry dates are commonly cited using patent-expiration dates that do not match the actual, settlement-negotiated first-launch dates — April 1, 2028 for most Eliquis filers and May 2026 for most Januvia filers — a distinction that materially changes go-to-market timing for any platform planning a generic-drug vertical.

FAQ

Is compounded semaglutide still legal in 2026?

Only narrowly. Mass-market, standard-dose compounded “copies” of Wegovy or Ozempic are no longer permitted because both drugs’ FDA shortage designations were resolved in 2025 and enforcement-discretion windows closed by May 22, 2025. Genuine patient-specific 503A compounding — for a documented clinical need such as an allergy to an inactive ingredient — remains legal.7,13

Why did Novo Nordisk end its partnership with Hims & Hers?

Novo Nordisk terminated the arrangement in June 2025, alleging Hims & Hers was selling mass-compounded semaglutide under a “false guise of personalization” and using deceptive marketing that implied the compounded product was equivalent to FDA-approved Wegovy.2,41 Hims & Hers’ CEO countered that Novo’s commercial team had pressured the company to steer patients toward Wegovy regardless of clinical fit.2

What happened with the DOJ referral in February 2026?

HHS General Counsel Mike Stuart referred Hims & Hers to the Department of Justice for investigation into potential Federal Food, Drug, and Cosmetic Act and Title 18 violations, one day after Novo Nordisk said it would sue over Hims & Hers’ $49 compounded Wegovy-pill copy. Hims & Hers withdrew the product the next day.11,12

Is Ro’s model actually safer from regulatory risk than Hims & Hers’?

Structurally, yes, in the sense that distributing an FDA-approved, on-label branded drug through a manufacturer’s own channel carries none of the FDCA misbranding exposure that marketing a compounded copy as equivalent does. Ro was not named in the FDA’s September 2025 warning-letter batch. Ro is not risk-free — it still operates under the same CPOM constraints — but its 2025–2026 regulatory footprint is smaller than Hims & Hers’.

What did the YourBio Health acquisition actually cost?

$153.0 million total: $142.4 million in cash plus $10.6 million in contingent consideration, according to public transaction filings. The deal closed January 30, 2026.29

When can generic Eliquis actually launch?

The composition-of-matter patent’s own extended expiration is November 21, 2026 (May 2027 with pediatric exclusivity), but BMS and Pfizer’s settlement agreements with most ANDA filers license generic entry starting April 1, 2028. A small number of later filers remain in active patent litigation, which could theoretically produce earlier entry for those specific companies if BMS and Pfizer lose.33,34

When can generic Januvia actually launch?

Merck’s settlements with more than two dozen generic manufacturers license U.S. entry starting in May 2026 for Januvia and Janumet and July 2026 for Janumet XR — both dates ahead of the underlying salt/polymorph patent’s own November 24, 2026 expiration.37,38

How big is Hims & Hers’ international business now?

International revenue grew more than 17-fold year over year to $131.4 million in Q2 2026, driven primarily by the June 2026 close of the Eucalyptus acquisition, which itself brought roughly 775,000 customers and a $450+ million annualized revenue run rate.2,21

Is the PBM satisfaction collapse still accelerating in 2026?

No. It fell sharply from 2024 (7.6) to 2025 (7.1) on PSG’s 10-point scale, but the 2026 survey shows it stabilizing at 7.2 — essentially flat versus 2025, though still well below the 2021 high of 8.2.41,42

Does DrugPatentWatch data change how these companies plan generic launches?

The core value is distinguishing a patent’s listed expiration date from the actual, litigation- or settlement-adjusted date generics may launch — as the Eliquis and Januvia cases above demonstrate, those two dates are frequently different by months or years, and building a go-to-market plan around the wrong one misprices the opportunity window.

References

  1. Frierlevitt, “Hims & Hers’ Compounded Wegovy Pill: A Swift Rise and Fall Under Regulatory Pressure,” 2026. https://www.frierlevitt.com/articles/hims-compounded-wegovy-fda-glp1-compounding-enforcement/
  2. Hims & Hers Health, Inc., “Reports Second Quarter 2026 Financial Results,” SEC Form 8-K, August 10, 2026. https://www.sec.gov/Archives/edgar/data/0001773751/000177375126000161/hims-20260630x8xkearningsr.htm
  3. Sacra, “Ro revenue, valuation & funding,” accessed 2026. https://sacra.com/c/ro/
  4. Hims & Hers Health Q2 Earnings Call Highlights, Yahoo Finance, 2026. https://finance.yahoo.com/healthcare/articles/hims-hers-health-q2-earnings-030356403.html
  5. Hims & Hers Health, Inc., “Reports Fourth Quarter and Full Year 2025 Financial Results,” SEC Form 8-K, February 23, 2026. https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/hims-20251231x8xkearningsr.htm
  6. Bounce Watch, “Ro — Funding, Investors & Signals 2026.” https://bouncewatch.com/company/ro
  7. MetabolicLedger, “FDA, Hims, and Novo: A Plain-English Timeline of the 2026 GLP-1 Compounding Cliff,” 2026. https://metabolicledger.com/regulatory/fda-compounding-cliff
  8. FDA, Warning Letter to Hims & Hers Health, Inc. dba Hims, MARCS-CMS 716567, September 9, 2025. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hims-hers-health-inc-dba-hims-716567-09092025
  9. FDA, Warning Letter to Hims & Hers Health, Inc. dba Hers, MARCS-CMS 716825, September 9, 2025. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hims-hers-health-inc-dba-hers-09092025
  10. Forbes, “Novo Nordisk Will Sue Hims & Hers For Undercutting Wegovy Pill With $49 Copy,” February 2026. https://www.forbes.com/sites/martinadilicosa/2026/02/05/hims-and-hers-will-undercut-wegovy-pill-with-49-copy-novo-stock-shudders/
  11. Mike Stuart, HHS General Counsel, public statement, February 6, 2026. https://x.com/HHSGCMikeStuart/status/2019882833041608990
  12. Frierlevitt, op. cit.
  13. PrecisionTelemed, “Is Compounded Semaglutide Legal in 2026? What Changed,” 2026. https://precisiontelemed.com/compounded-semaglutide-legal-2026/
  14. BioSpace, “Novo Nordisk’s Termination of Hims & Hers Deal Reignites Compounding Row,” 2025. https://www.biospace.com/business/novo-nordisks-termination-of-hims-hers-deal-reignites-compounding-row
  15. Hims & Hers Health, Inc., “Completes Acquisition of Eucalyptus,” SEC Form 8-K, June 2, 2026. https://www.sec.gov/Archives/edgar/data/0001773751/000177375126000091/ex991pressreleaserercfeuc.htm
  16. Hims & Hers Health, Inc., Form 10-Q for Q2 2026, SEC. https://www.sec.gov/Archives/edgar/data/0001773751/000177375126000163/hims-20260630.htm
  17. Montana Matos, “HIMS Q2 2026: The Money Machine Is Starting to Scale,” Substack, 2026. https://montanamatos.substack.com/p/hims-q2-2026-earnings-analysis
  18. Hims & Hers Health, Inc., Q4/FY2025 Shareholder Letter, SEC Form 8-K exhibit. https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/finalq42025shareholderle.htm
  19. Hims & Hers Health, Inc., “Completes Acquisition of Eucalyptus,” op. cit.
  20. CNBC, “Hims & Hers Health to acquire Australia’s Eucalyptus for up to $1.15 billion,” February 19, 2026. https://www.cnbc.com/2026/02/19/hims-hers-health-to-acquire-australias-eucalyptus-for-up-to-1point15-billion.html
  21. HLTH, “Hims & Hers Acquires Eucalyptus Health in $1.15bn International Expansion,” 2026. https://hlth.com/insights/news/hims-and-hers-acquires-eucalyptus-health-in-1-15bn-international-expansion-2026-02-20
  22. FierceHealthcare, “Ro teams up with Eli Lilly to offer single-dose vials of weight loss drug Zepbound,” December 2024. https://www.fiercehealthcare.com/providers/ro-teams-eli-lilly-offer-single-dose-vials-weight-loss-drug-zepbound
  23. PR Newswire, “Ro Launches Eli Lilly’s KwikPen, Offering Patients a More Convenient Way to Take Zepbound,” April 2, 2026. https://www.prnewswire.com/news-releases/ro-launches-eli-lillys-kwikpen-offering-patients-a-more-convenient-way-to-take-zepbound-302733095.html
  24. Tracxn, “Ro — 2026 Company Profile,” citing Novo Nordisk Wegovy pill launch partnership, January 2026. https://tracxn.com/d/companies/ro/__7mMbSlTFwMAEdl0-pCAnUovEI2SOTKFws6Rp8wnfSjQ
  25. Rock Health, “Ro acquires Modern Fertility: Segment-specific M&A another front in the platform wars,” 2021. https://rockhealth.com/ro-acquires-modern-fertility-segment-specific-ma-another-front-in-the-platform-wars/
  26. FierceHealthcare, “Ro scoops up at-home testing startup Kit on the heels of Workpath, Modern Fertility acquisitions,” 2021. https://www.fiercehealthcare.com/tech/ro-scoops-up-at-home-testing-startup-kit-heels-workpath-modern-fertility-acquisitions
  27. Fast Company, “Ro acquires sperm collection and testing startup Dadi for $100 million,” 2022. https://www.fastcompany.com/90725974/ro-acquires-dadi-sperm-collection
  28. Investing.com, “Hims & Hers to acquire YourBio Health for painless blood sampling tech,” December 3, 2025. https://www.investing.com/news/company-news/hims–hers-to-acquire-yourbio-health-for-painless-blood-sampling-tech-93CH-4388683
  29. Whiteford Research Biobase, “Seventh Sense Biosystems,” transaction-value data. https://biobase.whitefordresearch.com/companies/seventh-sense-biosystems
  30. FierceHealthcare, “Hims & Hers expands into diagnostics, moves into Canada as it evolves DTC telehealth platform,” 2025. https://www.fiercehealthcare.com/health-tech/hims-hers-expands-diagnostics-moves-canada-it-navigates-direct-consumer-prescription
  31. Hims Inc., “Hims & Hers to Acquire YourBio Health, Pioneer Behind Advanced, Pain-Free Blood Sampling Technology,” investor press release. https://investors.hims.com/news/news-details/2025/Hims–Hers-to-Acquire-YourBio-Health-Pioneer-Behind-Advanced-Pain-Free-Blood-Sampling-Technology/default.aspx
  32. i-MAK, “Overpatented, Overpriced 2025: A Data Brief on Medicare-Negotiated Drugs: Eliquis, Ozempic, Rybelsus and Wegovy.” https://www.i-mak.org/overpatented/
  33. DrugPatentWatch, “Why a Spreadsheet of Expiration Dates Isn’t a Strategy — It’s a Liability With a Due Date,” 2026. https://www.drugpatentwatch.com/blog/why-a-spreadsheet-of-expiration-dates-isnt-a-strategy-its-a-liability-with-a-due-date/
  34. Bristol Myers Squibb Co., Form 10-Q for Q1 2026, SEC, Note 18 Legal Proceedings. https://www.sec.gov/Archives/edgar/data/0000014272/000001427226000010/bmy-20260331.htm
  35. Bristol Myers Squibb Co., Form 10-Q for Q2 2026, SEC, Note 18 Legal Proceedings. https://www.sec.gov/Archives/edgar/data/0000014272/000001427226000020/bmy-20260630.htm
  36. Merck & Co., Inc., Form 10-Q for Q1 2026, SEC. https://www.sec.gov/Archives/edgar/data/0000310158/000162828026029802/mrk-20260331.htm
  37. Pharmaceutical Technology, “Merck obtains favourable US court ruling on sitagliptin patent lawsuit.” https://www.pharmaceutical-technology.com/news/merck-sitagliptin-patent-lawsuit/
  38. Merck & Co., Inc., Form 10-Q for Q2 2026, SEC. https://www.sec.gov/Archives/edgar/data/0000310158/000031015826000212/mrk-20260630.htm
  39. Merck.com, “U.S. District Court Rules In Favor of Merck in Sitagliptin Phosphate Patent Lawsuit.” https://www.merck.com/news/u-s-district-court-rules-in-favor-of-merck-in-sitagliptin-phosphate-patent-lawsuit/
  40. Yahoo Finance, “Novo Nordisk (NVO) Terminates Hims & Hers Partnership Over Wegovy Sales Issues,” 2025. https://finance.yahoo.com/news/novo-nordisk-nvo-terminates-hims-094130609.html
  41. Pharmaceutical Strategies Group, “Publishes 2025 Pharmacy Benefit Manager Customer Satisfaction Report,” September 23, 2025. https://finance.yahoo.com/news/pharmaceutical-strategies-group-publishes-2025-140000847.html
  42. Insurance Business Magazine, “PBM renewal scores hit decade low as plan sponsors eye the market,” 2026. https://www.insurancebusinessmag.com/us/news/benefits/pbm-renewal-scores-hit-decade-low-as-plan-sponsors-eye-the-market-591624.aspx

Make Better Decisions with DrugPatentWatch

» Start Your Free Trial Today «

Copyright © DrugPatentWatch. Originally published at

Related Posts:

Related Posts

DrugPatentWatch - Transform Data into Market Domination